← All claims

Sweeteners · Metabolic & Cardiometabolic

erythritol increases cardiovascular disease

Leans support Sweeteners

Part of: • erythritol

RefutedContestedStrong support
consensus score 0.59

Evidence ladder

How far up the ladder this claim has climbed. A high consensus on a low rung means "consistent so far," not "proven in people."

Top evidence so far: Population patterns (Observational)

MechanismIn-vitroAnimalObservationalRCTMeta-analysis

How the studies fall

4 support 0 contradict 0 tested null 3 mixed · 7 sources, 3 independent groups

What the evidence shows

A single high-profile research program (Hazen lab, *Nature Medicine* 2023) reported that higher circulating erythritol predicts 3-year major adverse cardiovascular events across three cohorts, and that erythritol enhances platelet reactivity and thrombosis in mechanistic models. Provocative and mechanistically coherent — **but graded `insufficient` on purpose**: it is essentially one group, not in

The evidence (7)

SourceGradeStanceQualityFinding
Abushamat et al.
2025 · JACC Adv
observational supports high ARIC cohort (n=4,006, independent of the original lab): higher circulating erythritol and its metabolite erythronate associated with incident cardiovascular events in older adults.
Berry et al.
2025 · J Appl Physiol
in-vitro supports moderate Independent in-vitro work: erythritol impaired brain microvascular endothelial cell function (oxidative stress, reduced nitric oxide) — mechanistic support.
Huang et al.
2025 · Cardiol Rev
observational mixed moderate Review of artificial sweeteners and CVD: erythritol among emerging concerns, evidence not yet conclusive.
Fan et al.
2025 · Am J Prev Cardiol
observational mixed moderate Two-sample Mendelian-randomization study of erythritol and CVD/stroke/diabetes: causal genetic evidence debated across sensitivity analyses (does not cleanly confirm causation).
Witkowski et al.
2024 · Arterioscler Thromb Vasc Biol
observational supports moderate Brief report (same group): erythritol ingestion, but not glucose, enhanced platelet reactivity and thrombosis potential in healthy volunteers.
Wolnerhanssen & Meyer-Gerspach
2025 · Cardiovasc Res
observational mixed moderate Review ('friend or foe?'): erythritol/xylitol cardiovascular signals real but confounded by endogenous production; net uncertain.
Witkowski et al.
2023 · Nat Med
observational supports high Nature Med: circulating erythritol associated with 3-yr MACE across 3 cohorts (adjusted HR ~1.8-2.2, top vs bottom quartile); erythritol enhanced platelet reactivity in vitro and thrombosis in vivo; ingestion in 8 volunteers raised plasma levels above prothrombotic thresholds for >2 days.

Disagree, or know a study we missed?

We grade by evidence, not opinions. The way to weigh in is to point us to a study we haven't cited (check the evidence table above first), or to flag a problem with one we have. Every submission is reviewed; if it holds up, the grade updates and shows in Science Changes Its Mind.

📚 Suggest a study ⚑ Flag / request reclassification

Opens a short form. You'll sign in with Google so submissions are tied to a real account — we don't display your identity, and we only accept a link we can verify (PubMed, DOI, ClinicalTrials.gov).

Educational only, not medical advice. Grades and scores reflect published evidence weighted by study design and quality; see the methodology.